Phenylketonuria Therapeutics Market Snapshot (2023 to 2033)

The global phenylketonuria therapeutics market is expected to garner a market value of US$ 1 billion in 2023 and is expected to accumulate a market value of US$ 2.28 billion by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for Phenylketonuria Therapeutics registered a CAGR of 5.2% in the historical period 2018 to 2022.

Phenylketonuria (PKU) is a rare inherited metabolic disorder that results in the inability of the body to break down an amino acid called phenylalanine. This leads to a buildup of phenylalanine in the blood, which can cause severe brain damage and other neurological problems if left untreated.

The current treatment for PKU involves a strict low-phenylalanine diet, which can be difficult to adhere to and often requires the use of specialized medical foods and supplements. In addition to dietary management, there are also pharmacological treatments available for PKU, including sapropterin dihydrochloride, which is a synthetic form of tetrahydrobiopterin (BH4), a co-factor required for phenylalanine metabolism.

The global market for PKU therapeutics is projected to grow in the coming years, driven by an increasing prevalence of PKU and a growing awareness of the disorder among healthcare professionals and patients.

Report Attribute Details
Expected Market Value (2023) US$ 1 billion
Anticipated Forecast Value (2033) US$ 2.28 billion
Projected Growth Rate (2023 to 2033) 8.6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Phenylketonuria Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for phenylketonuria therapeutics reflected a value of 5.2% during the historical period, 2018 to 2022. One of the key drivers of market growth is the increasing prevalence of PKU worldwide. According to a report by the National Organization for Rare Disorders, PKU affects approximately one in every 10,000 to 15,000 newborns worldwide. This number is expected to increase due to factors such as increased genetic testing and newborn screening.

Another factor contributing to market growth is the increasing awareness of PKU among healthcare professionals and patients. As awareness of the disorder grows, there is a growing demand for effective treatments that can improve patient outcomes and quality of life.

In addition, the market is driven by the introduction of novel therapies and enhancements to existing products. Pharmaceutical companies are investing heavily in research and development to introduce new treatments and improve existing ones. Overall, the market for phenylketonuria therapeutics is expected to register a CAGR of 8.6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Phenylketonuria Therapeutics Market?

Increasing Prevalence of Phenylketonuria to Push Market Growth

Phenylketonuria (PKU) is a rare genetic disorder that affects the body's ability to process the amino acid phenylalanine. If left untreated, it can cause intellectual disability and other health problems. As a result, the demand for effective treatments for the disorder is growing, and this is one of the most prominent drivers of the Phenylketonuria therapeutics market.

Another key driver is the technological advancements in PKU diagnostics. These advancements have led to earlier and more accurate diagnosis of the disorder, which has increased demand for PKU therapeutics. Early diagnosis can also help prevent the development of more severe symptoms of the disorder.

In addition to this, governments around the world are taking initiatives to raise awareness about PKU and to fund research and development of effective therapeutics for the disorder. This has helped to create a more favorable regulatory environment, as well as increase funding for research and development. The growing support for PKU research and development is also driving the demand for new and innovative treatments for the disorder.

Finally, the increasing prevalence of PKU is also a driver of the Phenylketonuria therapeutics market. The disorder is becoming more common worldwide, which has led to an increase in the number of patients seeking treatment for the condition. As more patients are diagnosed with PKU, the demand for effective therapeutics will continue to grow.

In conclusion, the Phenylketonuria therapeutics market is being driven by a combination of factors, including the increasing prevalence of PKU, technological advancements in PKU diagnostics, government initiatives and funding, and growing demand for effective treatments for the disorder. These drivers are expected to continue to fuel growth in the PKU therapeutics market in the coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Phenylketonuria Therapeutics Market?

Expensive Cost of Treatment to restrict Market Growth

One of the significant challenges faced by the PKU therapeutics market is the lack of awareness and underdiagnosis of the disorder. Many patients with PKU are undiagnosed or misdiagnosed, which can lead to delayed treatment and poor health outcomes.

Moreover, the cost of PKU treatment can be high, making it difficult for patients and families to afford. The cost of specialized diets, medical foods, and supplements can add up quickly, and many insurance plans do not cover the full cost of treatment. Currently, there are limited treatment options available for PKU, and many patients do not respond well to existing treatments. This has led to a growing need for new and more effective treatments.

The phenylketonuria therapeutics market faces several challenges, including limited awareness and diagnosis, high cost of treatment, limited treatment options, compliance issues, and social stigma and isolation. Addressing these challenges will require collaboration among patients, healthcare providers, researchers, and policymakers to improve diagnosis, develop more affordable and effective treatments, and provide support and resources for patients and their families.

Region-Wise Insights

How is the Phenylketonuria Therapeutics Market Turning Out in the South & East Asia Region?

Increasing awareness and diagnosis of the condition Shaping Landscape for Phenylketonuria Therapeutics in South & East Asia

The phenylketonuria (PKU) therapeutics market in the South & East Asia region is still developing, but there is a growing demand for effective treatments for PKU. PKU is a rare disorder, and the prevalence of the condition varies widely across the region. However, with the increasing availability of advanced diagnostic tools and increasing awareness about PKU, the market for PKU therapeutics is expected to grow in the region.

One of the key factors driving the growth of the PKU therapeutics market in the South & East Asia region is the increasing number of diagnosed patients with PKU. As healthcare infrastructure in the region continues to improve, more patients are being diagnosed with the condition, creating a growing demand for PKU therapeutics.

The cost of PKU treatment is also a significant factor in the South & East Asia region. In many countries, the cost of PKU treatment can be high, and access to specialized medical foods and supplements can be limited. However, with increasing awareness about the disorder, more government and private organizations are coming forward to support patients and improve access to treatment.

Another factor driving the growth of the PKU therapeutics market in the region is the increasing number of research studies and clinical trials focused on PKU. These studies are contributing to the development of new and innovative treatments for PKU, which is expected to expand the treatment options available for patients in the region. In conclusion, the PKU therapeutics market in the South & East Asia region is still developing, but there is a growing demand for effective treatments.

What are the Factors Boosting the Market for Phenylketonuria Therapeutics in North America?

Increasing Focus on Technological Advancements shaping the landscape for Phenylketonuria Therapeutics in North America

The Phenylketonuria Therapeutics market in North America is expected to experience significant growth in the coming years, driven by several factors. One of the primary drivers of market growth is the high prevalence of underlying medical conditions that can lead to Phenylketonuria. These conditions are becoming increasingly common in North America, particularly among the aging population, and are contributing to a growing demand for innovative and effective treatments for Phenylketonuria.

In addition to the increasing prevalence of underlying medical conditions, the market is also being fueled by advances in technology and research. New diagnostic tools and treatment options are being developed, which are expected to improve outcomes for patients with Phenylketonuria.

Another key factor driving the phenylketonuria therapeutics market in North America is the high level of awareness and understanding of the condition among healthcare providers and the general public. This has led to increased diagnosis rates and better management of the condition, which is contributing to improved patient outcomes.

Finally, the presence of well-established healthcare infrastructure and a high level of investment in research and development in North America are also expected to boost market growth. This has created a favorable environment for the development and commercialization of new and innovative products and treatments for Phenylketonuria.

Overall, the phenylketonuria therapeutics market in North America is poised for significant growth in the coming years, expected to accumulate 40% of global revenues in 2023. This growth is likely to be driven by a range of factors including increasing prevalence of underlying medical conditions, advances in technology and research, high levels of awareness and understanding, and a favorable healthcare infrastructure and investment environment.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Route of Administration, Which Segment is Likely to Account for a Significant Share?

Parenteral route of administration to hold a significant share and push market growth

The injectable route of administration is likely to account for a significant share of the Phenylketonuria Therapeutics market. This is due to the effectiveness of parenteral treatments, which can be administered directly into the bloodstream or affected area for faster and more targeted delivery of medication.

Parenteral treatments are also preferred in cases where oral medications may not be suitable, such as for patients with difficulty swallowing or those who require higher doses that may not be feasible with oral medications. In addition, several established parenteral treatments for Phenylketonuria are already available on the market, which further contributes to the dominance of the parenteral segment.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies segment to hold a significant share and push market growth

Hospitals and specialty clinics are often the first point of contact for patients with Phenylketonuria, as they provide specialized care and access to diagnostic tools and treatments. These facilities also have the expertise and resources to provide comprehensive care to patients with complex or severe cases of Phenylketonuria.

In addition, many of the treatments for Phenylketonuria require specialized administration or monitoring, such as intravitreal injections or electroretinography testing, which are typically performed in hospitals or specialty clinics. This further contributes to the dominance of these distribution channels in the Phenylketonuria Therapeutics market.

Overall, hospitals and specialty clinics are likely to continue to account for a significant share of the Phenylketonuria Therapeutics market, driven by the specialized care and expertise they provide. However, as patient preferences and healthcare delivery models continue to evolve, the market share of the various distribution channels may shift over time.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Cigna, BioMarin Pharmaceuticals, Codexis, Inc., Erytech Pharma, SOM Innovation Biotech SL, Synthetic Biologics, Inc., Retrophin, Inc., Danone, Censa Pharmaceuticals, Homology Medicines, Inc., along with healthcare providers and technology companies among other global players.

  • In January 2023, Jnana Therapeutics was granted clearance by the FDA for its Investigational New Drug (IND) application for JNT-517, a drug being developed to treat phenylketonuria (PKU), a condition that is difficult to treat. The biotechnology company is using its advanced chemoproteomics platform to discover drugs for challenging targets. The Phase 1 program of JNT-517 is currently underway in healthy volunteers in Australia, and will expand to include clinical sites in the USA The Phase 1b sub-study will evaluate the drug's effectiveness in individuals with PKU, with the potential to demonstrate clinical proof of concept that supports a subsequent registrational program.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1 billion
Market Value in 2033 US$ 2.28 billion
Growth Rate CAGR of 8.6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Route of Administration
  • Distribution Channel
  • Drug Class
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • The Cigna Group
  • BioMarin Pharmaceutical Inc.
  • Codexis Inc.
  • Erytech Pharma S.A
  • SOM Innovation Biotech S.A
  • Synthetic Biologics, Inc. (Theriva)
  • Retrophin Inc. (Travere Therapeutics)
  • Danone S.A.
  • Censa Pharmaceuticals (PTC Therapeutics)
  • Homology Medicines Inc.
Customization Available Upon Request

Key Segments Profiled in the Phenylketonuria Therapeutics Industry Survey

Drug Type:

  • Kuvan
  • Playnziq

Route of Administration:

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What Big is the Global Phenylketonuria Therapeutics Market Presently?

In 2023, the overall market is estimated to generate a revenue sum of nearly US$ 1 billion.

Which Route of Administration Generates the Highest Revenue for Phenylketonuria Therapeutics Market?

The injectable route of administration segment generates higher revenue for the global market.

What Makes the North America the Leading Region for Global Phenylketonuria Therapeutics Market?

The region is expected to account for 40% global revenue due to the presence of many leading market players.

What is the Share of South & East Asian Countries in the Global Market?

The overall regional market has a limited share but is expected to grow at a faster rate through 2033.

Who will be the Leading Market Players in Phenylketonuria Therapeutics Services?

Cigna, BioMarin, and Codexis are known to be the leading market players.

Table of Content

1. Executive Summary | Phenylketonuria Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Kuvan

        5.3.2. Playnziq

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Parenteral

        6.3.3. Intravenous

        6.3.4. Subcutaneous

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospitals Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East & Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East & Africa

        15.2.2. By Drug Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.S.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Cigna

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. BioMarin Pharmaceutical Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Codexis, Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Erytech Pharma S.A

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. SOM Innovation Biotech S.A

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Synthetic Biologics, Inc. (Theriva)

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Retrophin, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Danone S.A

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Censa Pharmaceuticals (PTC Therapeutics)

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Homology Medicines, Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurodegenerative Disease Market

March 2022

REP-GB-1052

May 2024

250 pages

Healthcare

Autoimmune Disease Therapeutics Market

February 2016

REP-GB-1238

July 2023

324 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Phenylketonuria Therapeutics Market